Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Stomach Neoplasms 4Sarcoma 2Endometrial Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Postoperative Complications 1Ovarian Neoplasms 1Neoplasms 1Motor Activity 1Lymphoma, Follicular 1Lung Neoplasms 1Gynecologic Surgical Procedures 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Frailty 1Coma 1Colonic Neoplasms 1Cerebrovascular Disorders 1Carcinoma, Hepatocellular 1Brain Injuries, Traumatic 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Enhanced Recovery After Surgery × Clear all
NCT02644603 2017-06-27

Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer

Shanghai Zhongshan Hospital

Phase NA Unknown
214 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡